Please login to the form below

Not currently logged in
Email:
Password:

Roche and Evotec form biomarker alliance

Roche and Evotec are to collaborate on protein-activity based biomarkers for Roche's oncology drugs under development

Roche and Evotec, a drug discovery company specialising in development partnerships, are to collaborate on protein-activity based biomarkers for Roche's oncology drugs under development.

Evotec will employ its PhosphoScout platform to discover protein-phosphorylation's that predict favourable dosage and efficacy of targeted cancer drugs in patients. Roche will be responsible for conducting clinical trials, as well as assessing the development of companion diagnostics for patient stratification.

Mike Burgess, global head of oncology at Roche Pharma Research and Exploratory Development, said: "We are very pleased to collaborate with Evotec and benefit from the PhosphoScout technology to identify appropriate pharmacodynamics and patient stratification biomarkers. They are core to the development of targeted therapeutics for cancer therapy."

Under the initial three-year term Roche and Evotec will conduct multiple biomarker programmes for therapeutic antibodies or small molecule inhibitors.

27th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics